EUCTR2018-002677-22-ES进行中（未招募）1 期
Doppler sonography of skin and nodal metastases as a predictor of clinical response to Talimogene Laherparepvec (T-VEC) in melanoma patients (T-VEC – US Doppler) - T-VEC – US Doppler
Fundació Clínic per a la Recerca Biomèdica0 个研究点目标入组 25 人开始时间: 2019年7月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Subject has provided informed consent prior to initiation of any study-specific
- •activities/procedures
- •-Male or female age = 18 years.
- •-Histologically confirmed diagnosis of malignant melanoma.
- •-Subjects with unresected stage IIIB to IVM1a melanoma
- •-Candidate for intralesional therapy defined as:
- •-at least 1 injectable cutaneous, subcutaneous or nodal melanoma lesion = 10 mm in longest
- •diameter or, multiple injectable melanoma lesions which in aggregate have a longest diameter of
- •= 10mm and measurable by sonography and positive Doppler signal.
- •-Measurable disease defined as one or more of the following:
- •-at least 1 melanoma lesion that can be accurately and serially measured in at least 2 dimensions
- •and for which the greatest diameter is = 10 mm as measured by contrast enhanced or spiral
- •computed tomography (CT) scan for nodal/soft tissue disease(including lymph nodes)
- •-at least 1 = 10 mm superficial cutaneous or subcutaneous melanoma lesion as measured by
- •-at least 1 = 10 mm superficial cutaneous or subcutaneous melanoma lesion as measured by
- •-multiple superficial melanoma lesions which in aggregate have a total diameter of = 10mm
- •-Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- •-Serum LDH levels = upper limit of normal (ULN) within 28 days prior to enrollment.
- •-Adequate organ function determined within 28 days prior to enrollment, defined as:
- •-Absolute neutrophil count (ANC) = 1,500/mm3
- •-Platelet count = 100,000/mm3
- •-Hemoglobin = 8 g/dL without need for hematopoietic growth factor or transfusion support
- •-Serum creatinine = 1.5 x ULN
- •-Serum bilirubin = 1.5 x ULN
- •-Aspartate amino transferase (AST) = 2.5 x ULN
- •-Alanine amino transferase (ALT) = 2.5 x ULN
- •-Alkaline phosphatase = 2.5 x ULN
- •-Serum albumin = 2.5 g/dL
- •-Coagulation
- •- International normalization ratio (INR) or prothrombin time (PT) £ 1.5 x ULN, unless the subject is receiving anticoagulant therapy, in which case PT and partial thromboplastin time (PTT)/ activated PTT (aPTT) must be within therapeutic range of intended use of anticoagulants.
- •·PTT or aPTT £ 1.5 x ULN, unless the subject is receiving anticoagulant therapy as long as PT and
- •PTT/aPTT is within therapeutic range of intended use of anticoagulants.
- •-Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to enrollment. If urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •-Primary ocular or mucosal melanoma
- •-Known active central nervous system (CNS) metastases. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids >10 mg/day of prednisone or equivalent. The exception does not include carcinomatosus meningitis which is excluded regardless of clinical stability.
- •-History or evidence of active autoimmune disease that requires systemic treatment (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •-Evidence of clinically significant immunosuppression such as the following: primary immunodeficiency state such as Severe Combined Immunodeficiency Disease receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within 7 days prior to enrollment.
- •-Concurrent opportunistic infection.
- •-Patients with allergy to contrast
- •-Subject has known sensitivity to talimogene laherparepvec or any of its components to be administered during dosing.
- •-Patients with a history of any ischemic event will be excluded
- •-Known to have acute or chronic active hepatitis B infection
- •-known to have acute of chronic active hepatitis C infection
- •-known to have human immunodeficiency virus (HIV) infection
- •-Active herpetic skin lesions or prior complications of HSV-1 infection (eg, herpetic keratitis or encephalitis)
- •-Requires intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (eg, acyclovir), other than intermittent topical use.
- •-Previous treatment with talimogene laherparepvec or any other oncolytic virus.
- •-Prior therapy with tumor vaccine.
- •-Received live vaccine within 28 days prior to enrollment.
- •-Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of talimogene laherparepvec.
- •-Female subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 3 months after the last dose of talimogene laherparepvec.
- •-Sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec.
- •-Subjects who are unwilling to minimize exposure with his/her blood or other body fluids to individuals who are at higher risks for HSV-1 induced complications such as immunosuppressed individuals, individuals known to have HIV infection, pregnant women, or infants under the age of 3 months, during talimogene laherparepvec treatment and through 30 days after the last dose of talimogene laherparepvec.
- •-Prior immunosuppressive, chemotherapy, radiotherapy (in which the field encompassed a planned injection site), biological cancer therapy, or major surgery within 28 days prior to enrollment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 28 days prior to enrollment. Adjuvant hormo
研究者
相似试验
招募中
不适用
Tissue Doppler Imaging: New Ultrasonographic Method for Evaluating Wall Motion of Cervical Esophagus during Swallowingpatients with globus sensation and/or dysphagiaJPRN-UMIN000005497Kawasaki Medical School100
尚未招募
不适用
Histologic diagnosis endoscopic ultrasound needles with and without franseen design :A randomized controlled trialCases which needs histlogical diagnosis by EUS-FNAJPRN-UMIN000033028Kitasato university medical center40
已完成
不适用
Sonographic and electrophysiological characterisation of peripheral nerves in patients with type 2 diabetesG63.2G61.8Diabetic polyneuropathyOther inflammatory polyneuropathiesDRKS00023026niversitätsklinik Jena, Klinik für Neurologie156
进行中（未招募）
1 期
ltrasonographic characterization of small nodules in cirrhotic patients using contrast media through splancnic infusion - NDMedDRA version: 9.1Level: LLTClassification code 10019641Term: Hepatic cirrhosishepatic cirrhosisEUCTR2007-005364-27-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI15
进行中（未招募）
1 期
Doppler ultrasound investigation of microvasculature in health and diseaseDiabetes mellitus HypertensionEUCTR2006-005406-32-GBBelfast City Hospital Trust120